The landscape of cardiac rehabilitation devices has witnessed a notable upswing in adoption rates, propelled by the escalating prevalence of cardiac diseases. This surge has, in turn, spurred leading market players to invest in the development of advanced cardiac rehabilitation devices. A case in point is the groundbreaking initiative undertaken by MedicAlgorithmics and its US subsidiary, Medi-Lynx Cardiac Monitoring LLC, in July 2018. This collaboration achieved a significant milestone with the receipt of clearance from the US Food and Drug Administration (FDA) for their innovative PocketECG Cardiac Rehabilitation System (CRS). The introduction of this state-of-the-art mobile cardiac rehabilitation system marks a paradigm shift in the realm of cardiac care, offering high-quality electrocardiogram (ECG) monitoring and automated arrhythmia detection during rehabilitation training. This milestone not only exemplifies the commitment to innovation within the healthcare industry but also opens up substantial opportunities for market players, projecting a promising trajectory for the growth of the cardiac rehabilitation devices market in the foreseeable future.
The PocketECG CRS, with its FDA clearance, exemplifies a fusion of cutting-edge technology and healthcare, addressing a critical need in the management of cardiac diseases. The system is strategically designed to elevate the quality of cardiac rehabilitation by providing comprehensive ECG monitoring, thereby enhancing the precision and effectiveness of rehabilitation training. The automated arrhythmia detection feature further amplifies its significance, offering a proactive approach to identifying irregular heart rhythms during rehabilitation sessions. This innovation is a testament to the evolving landscape of cardiac rehabilitation devices, where advancements are not only geared towards monitoring but also towards real-time insights that contribute to more personalized and effective care.
The successful development and regulatory clearance of the PocketECG CRS signify a breakthrough for the healthcare industry and herald a new era in cardiac rehabilitation. This achievement is indicative of the industry's commitment to leveraging technological advancements to address the complex challenges posed by cardiac diseases. As more market players embrace a proactive stance towards innovation, the collective impact is expected to redefine the standards of care in cardiac rehabilitation, thereby contributing substantially to the overall growth of the market.
The introduction of advanced cardiac rehabilitation devices, such as the PocketECG CRS, has far-reaching implications for both healthcare providers and patients. For healthcare professionals, these devices offer a more comprehensive and nuanced understanding of patients' cardiac health during rehabilitation. The real-time data generated by such devices enables healthcare providers to tailor rehabilitation programs with greater precision, taking into account individual variations and responses. This level of personalization not only enhances the quality of care but also contributes to more favorable outcomes for patients recovering from cardiac events.
Patients, on the other hand, stand to benefit from the increased accessibility and effectiveness of cardiac rehabilitation programs facilitated by advanced devices. The integration of automated arrhythmia detection provides an additional layer of safety and vigilance during rehabilitation training, fostering a sense of security for individuals on their journey to cardiac recovery. Moreover, the mobility and convenience offered by systems like the PocketECG CRS empower patients to actively engage in rehabilitation, promoting a more participatory approach to their own health and well-being.
The market response to the introduction of advanced cardiac rehabilitation devices has been encouraging, reflecting the growing recognition of the pivotal role these innovations play in enhancing patient care. The success of initiatives like the PocketECG CRS underscores the market's receptivity to transformative technologies that elevate the standards of cardiac rehabilitation. As the momentum continues to build, it is anticipated that this trend will catalyze a wave of investments and innovations from other market players, fostering a dynamic and competitive landscape for cardiac rehabilitation devices.
Looking ahead, the prospects for the cardiac rehabilitation devices market appear promising, driven by the convergence of technological innovation, regulatory support, and the imperative to address the rising burden of cardiac diseases. The heightened awareness of the importance of cardiac rehabilitation, coupled with the positive outcomes associated with advanced devices, is expected to drive sustained growth in the market. The increasing collaboration between technology firms, healthcare providers, and regulatory bodies further paves the way for continued advancements, ensuring that cardiac rehabilitation devices continue to evolve to meet the evolving needs of patients and healthcare systems alike.
In conclusion, the surge in adoption rates of cardiac rehabilitation devices, exemplified by the success of the PocketECG CRS, heralds a transformative era in cardiac care. The convergence of technological prowess and healthcare objectives is redefining the landscape, offering innovative solutions that enhance the precision, safety, and effectiveness of cardiac rehabilitation. This paradigm shift not only opens up substantial opportunities for market players but also holds the promise of a future where advanced cardiac rehabilitation devices become integral to the standard of care, contributing significantly to the well-being of individuals on their journey to cardiac recovery.
Report Attribute/Metric | Details |
---|---|
Market Opportunities | Integration of cardiac rehabilitation devices with artificial intelligence (AI) |
Market Dynamics | Advancement in healthcare technologies and high-intensity training, unhealthy lifestyles practiced by people of all ages, and increase in heart-related issues in recent times |
Cardiac Rehabilitation Devices Market Size was valued at USD 1.4 Billion in 2023. The Cardiac Rehabilitation Devices market Phase is projected to grow from USD 1.48 Billion in 2024 to USD 2.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.08% during the forecast period (2024 - 2032). The development of medical technology, intense training, unhealthy lifestyles adopted by people of all ages, and the current rise in heart-related problems, are the key market drivers enhancing the market growth.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
In June 2023, NorthShore – Edward-Elmhurst Health (NS-EEH), the third-largest health system in Illinois that caters to 1.5 million patients in the Chicagoland area, and Motiv, a rising innovator in cardiology care, have jointly announced the development of the first-ever virtual cardiac recovery program for patients to use at home. This program will also include integrated support for behavioral health. The program tackles the difficulties linked to conventional cardiac rehabilitation by offering a tailored and convenient approach, which includes individualized health coaching and behavioral health assistance. NorthShore - Edward-Elmhurst Health's Highland Park Hospital patients will get the initial chance to participate in a six-month program. The program is already open and is expected to be extended to other cardiac patients later this year. The chance will be extended to patients who have undergone a cardiac incident and demonstrate potential advantages from engaging in the post-discharge in-home virtual cardiac recovery program. Following a meeting with their cardiologist, individuals who express a desire to participate will be contacted by Motiv in order to arrange their initial session.
In January 2023, UltraLinQ Healthcare Solutions introduces a novel patient monitoring approach that revolutionizes the diagnosis of cardiac arrhythmias. The company will present an UltraLinQ Holter Service, powered by LifeSignals, which is a comprehensive Wireless Holter Monitoring ECG Analysis and Reporting System. This system provides wireless ECG recording using high-quality wearable biosensors. Research has indicated that 45% of arrhythmias remain unnoticed while using a 24-hour Holter monitoring period in regular clinical practice. Extending the duration of monitoring to seven days can significantly enhance the identification of all types of arrhythmias, resulting in an over 97% detection rate and subsequently lowering the likelihood of stroke. The UltraLinQ Holter Service is a comprehensive solution that allows hospitals and specialized clinics to deliver extended Holter services to patients, whether they are visiting the clinics or receiving care remotely from their homes. The gadget is designed to monitor the patient's heart rhythm throughout their regular daily activities. It can collect data for a maximum of seven days and allows certified cardiac technicians to provide Holter reports within 36 hours. The approach employs a pay-per-use paradigm, which grants hospitals increased flexibility in delivering care to a broader range of patients, without overwhelming healthcare personnel.
Dynamic technological discoveries and advancements are to blame for this increase. The term "tele-cardiac rehabilitation" refers to rehabilitation therapies delivered remotely via telecommunications and information technology. Potentially reducing time, distance, and financial constraints is tele-cardiac rehabilitation. E-cardiology and e-health have advanced significantly in recent years and are anticipated to have an impact on the management and prevention of cardiovascular disease in the near future. Government support is regarded as one of the market drivers with a high impact rendering. For instance, the Centres for Disease Control and Prevention and the Centres for Medicare and Medicaid Services jointly lead the Million Hearts national campaign. By 2017, this effort hopes to stop over a million heart attacks and strokes. In order to improve American residents' health and help them live longer, healthier lives, this project brings together new and existing programmes. ly, the prevalence of lifestyle-related illnesses like obesity, diabetes, and cardiovascular disease is on the rise, which has a significant impact on the expansion of cardiac rehabilitation. Cardiovascular disease is identified as the primary cause of death in the Heart Disease and Stroke Statistics, 2017, a study by the American Heart Association, which accounts for close to 801,000 deaths in the U.S.
CR is a medical advancement that helps to lower weight and improve cardiovascular health. Combining these medical techniques with platforms like artificial intelligence, machine learning, and especially the internet of things (IoT) transforms the field and helps patients with cardiovascular illnesses. The market for cardiac rehabilitation devices provides the healthcare sector with a number of alternatives, including supporting patients in treating their heart conditions and lowering cholesterol, obesity, stress levels, and blood pressure. This is made possible by lower stress levels and better physiological wellness. These factors make treating cardiovascular disorders more effective, which boosts demand for cardiac rehabilitation equipment in new situations. For instance, InBody, a pioneer in body composition technology, unveiled the BP 170 blood pressure monitor in February 2022. This device enables users to track and self-record significant metrics at home.
The market for cardiac rehabilitation is expanding as a result of an increase in the prevalence of cardiovascular diseases and a rise in the demand for minimally invasive procedures. Furthermore, as a result of the rise in diabetes and obesity prevalence—both of which are known to induce cardiac illnesses—a considerable number of significant businesses have created new preventive technology. Cardiovascular illness was more common in COVID-19 patients, with myocardial injury being the most common diagnosis. As a result, individuals with COVD-19 were more likely to have a wide range of cardiovascular problems, which increased the need for the use of cardiac rehabilitation equipment. Thus, driving the Cardiac Rehabilitation Devices market revenue.
The Cardiac Rehabilitation Devices market segmentation, based on Device Type, includes Elliptical Trainer, Rower, Blood Pressure Monitor, Treadmill, Stabilization Ball, and Heart Rate Monitor. Treadmill segment dominated the market in 2022. According to the projection for the market for cardiac rehabilitation devices, this trend is expected to continue during the projected period. The prevalence of cardiovascular illnesses and the increased demand for this equipment when conducting cardiac rehabilitation programmes in various contexts are the main causes of the dominance.
The Cardiac Rehabilitation Devices market segmentation, based on End User, includes Rehab Centers, Research Centers, Specialty Centers, Hospitals, and Clinics. Rehab centers segment dominated the Cardiac Rehabilitation Devices market in 2022. This is a result of rising health consciousness among the populace and a rise in the quantity of rehabilitation facilities providing rehabilitation therapy in both developed and developing nations. Throughout the predicted period, it is anticipated that this tendency would persist.
The Cardiac Rehabilitation Devices market segmentation, based on Patient Type, includes Percutaneous Coronary Intervention, Myocardial Ischemia, Coronary Artery Bypass Grafting, and Coronary Artery Disease. Coronary artery disease segment dominated the Cardiac Rehabilitation Devices market in 2022. Throughout the predicted period, it is anticipated that this tendency would persist. However, because obstructive coronary artery disease is becoming more common among the general population, percutaneous coronary.
The Cardiac Rehabilitation Devices market segmentation, based on Phase, includes Phase I, Phase II, and Phase III. Phase III segment dominated the market in 2022. This is due to the fact that they include digital metres for the convenience and improved experience of heart patients.
Figure 1 Cardiac Rehabilitation Devices Market, by Phase, 2022 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The Asia Pacific Cardiac Rehabilitation Devices market dominated this market in 2022 (45.80%). This is a result of the region's expanding infrastructure, use of cutting-edge technology, rise in the number of people who place a high priority on exercise and health, and growing senior population. It is predicted that the adoption of technological innovation and expanded infrastructure will cause this increase. The need for cardiac rehabilitation equipment is increasing as the population ages and people's awareness of fitness and health grows. Moreover, China’s Cardiac Rehabilitation Devices market held the largest market share, and the Indian Cardiac Rehabilitation Devices market was the fastest growing market in the Asia-Pacific region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 CARDIAC REHABILITATION DEVICES MARKET SHARE BY REGION 2022 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
The North America Cardiac Rehabilitation Devices Market is expected to register significant growth from 2024 to 2032. This is because cardiovascular disorders like hypertension, strokes, and coronary heart disease are becoming more prevalent in the area. The United States bears a disproportionately large share of the burden of cardiovascular disease in North America because of its sizable population and evolving lifestyle. The top cause of death in the US, according to estimates, is heart disease. Further, the U.S. Cardiac Rehabilitation Devices market held the largest market share, and the Canada Cardiac Rehabilitation Devices market was the fastest growing market in the North America region.
Europe Cardiac Rehabilitation Devices market accounted for the healthy market share in 2023. The surge in product introductions is to blame for this. Additionally, a rise in the number of regulatory approvals in Europe's industrialised nations had a favourable impact on market expansion. Further, the German Cardiac Rehabilitation Devices market held the largest market share, and the U.K Cardiac Rehabilitation Devices market was the fastest growing market in the European region
Cardiac Rehabilitation Devices Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Cardiac Rehabilitation Devices market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Cardiac Rehabilitation Devices Industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Cardiac Rehabilitation Devices Industry to benefit clients and increase the market sector. In recent years, the Cardiac Rehabilitation Devices Industry has offered some of the most significant advantages to medicine. Major players in the Cardiac Rehabilitation Devices market, including Brunswick Corporation, Core Health & Fitness LLC, Amer Sports, OMRON Corporation, Honey well International Inc., The ScottCare Corporation, BioTelemetry Inc., Schiller, LSI, Ergoline GmbH, Scifit, Ball Dynamics International LLC, Core Health & Fitness LLC, Philips, Smiths Group, Halma plc., LifeWatch AG, and Patterson Companies Inc., are attempting to increase market demand by investing in research and development operations.
A company that offers molecular diagnostic testing services is Royal Philips Electronics. The business offers a platform for molecular diagnostic testing to examine illness samples. A milestone for the efforts to meet the needs to combat SCA (Sudden Cardiac Arrest) was reached in September 2019 when Royal Philips announced the shipment of its two million AEDs.
Halma is made up of 44 active firms that are all distributedly managed. The company strives to create a safer, cleaner, and healthier world through its goods. The organization's three business divisions are safety, environmental and analytical sciences, and healthcare. Smoke detectors, medical supplies, door sensors, and water purification are among Halma's offerings. The majority of the group's products are specialised and face little rivalry. The United States, Europe, and the United Kingdom account for more than 75% of sales. The London Stock Exchange lists Halma. FluxData, which develops and produces cutting-edge digital and multispectral imaging systems for a variety of industries, including the industrial and medical sectors, was purchased by Halma plc in January 2017.
Key Companies in the Cardiac Rehabilitation Devices market include
Cardiac Rehabilitation Devices Industry Developments
June 2022 With the G866 Front-Drive Elliptical, SportsArt introduced the ECO-POWR series. ECO-POWR. Equipment for cardio, strength training, and rehabilitation uses ECO-POWR for the residential, medical, and fitness industries.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)